Composition, form of production and packaging
The solution for ingestion, local and external use is transparent, yellow in color of varying intensity, a greenish shade is allowed.
1 f.
a mixture of sterile phagolysates of bacteria Proteus vulgaris, Proteus mirabilis and enteropathogenic Escherichia coli of various serogroups of 100 ml
Excipients: 8-hydroxyquinoline sulfate monohydrate 0.0001 g / ml.
100 ml - bottles (1) - packs of cardboard.
100 ml - bottles (1) - packs of cardboard.
The solution for ingestion, local and external use is transparent, yellow in color of varying intensity, a greenish shade is allowed.
1 f.
a mixture of sterile phagolysates of bacteria Proteus vulgaris, Proteus mirabilis and enteropathogenic Escherichia coli of various serogroups of 20 ml
Excipients: 8-hydroxyquinoline sulfate monohydrate 0.0001 g / ml.
20 ml - bottles (8) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
The drug causes a specific lysis of bacteria Proteus vulgaris, Proteus mirabilis, Escherichia coli.
INDICATIONS
Treatment and prevention of purulent-inflammatory and enteral diseases, dysbacteriosis, bacterium-induced protea and enteropathogenic E. coli as part of complex therapy:
- Diseases of the ear, throat, nose, respiratory tract and lungs (inflammation of the sinuses of the nose, middle ear, sore throat, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleurisy);
- surgical infections (suppuration of wounds, burns, abscess, phlegmon, furuncles, carbuncles, hydroadenitis, panaritium, paraproctitis, mastitis, bursitis, osteomyelitis);
- urogenital infections (urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingoophoritis);
- enteral infections (gastroenterocolitis, cholecystitis), intestinal dysbacteriosis;
- generalized septic diseases;
- purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis, etc.);
- other diseases caused by a protea and E. coli.
An important condition for effective phage therapy is the preliminary determination of the pathogenicity of the pathogen.
DOSING MODE
The drug is used for oral administration (through the mouth), rectal administration, applications, irrigation, insertion into the wound cavity, vagina, uterus, nose, sinuses and drained cavities.
Recommended dosage of the drug
Age of the patient Dose for 1 dose (ml)
inside in enema
0-6 months 5 5-10
6-12 months 10 10-20
from 1 year to 3 years 15 20-30
from 3 to 8 years 15-20 30-40
from 8 years and older 20-30 40-50
Treatment of purulent-inflammatory diseases with localized lesions should be carried out simultaneously both topically and by taking the drug inside within 7-20 days (according to clinical indications).
In the event that chemical antiseptics were used before the bacteriophage was used to treat wounds, the wound should be thoroughly washed with sterile 0.9% sodium chloride solution.
Depending on the source of infection, the bacteriophage is used:
1. In the form of irrigation, lotion and tamponization in a volume of up to 200 ml, depending on the size of the affected area. In the abscess after removal of purulent contents with puncture, the drug is administered in an amount less than the volume of the removed pus. When osteomyelitis after appropriate surgical treatment, a bacteriophage 10-20 ml is poured into the wound.
2. When injected into the cavity (pleural, articular and other limited cavities) to 100 ml, then leave capillary drainage, through which the bacteriophage is injected for several days.
3. For cystitis, pyelonephritis, urethritis, the drug is taken orally. In case the cavity of the bladder or renal pelvis is drained, the bacteriophage is injected through the cystostomy or nephrostomy 1-2 times a day for 20-50 ml in the bladder and 5-7 ml in the renal pelvis.
4. With purulent-inflammatory gynecological diseases, the drug is injected into the cavity of the vagina, the uterus in a dose of 5-10 ml once daily, with colpitis - 10 ml irrigation or tamponing 2 times a day. Tampons are pawned for 2 hours.
5. With purulent-inflammatory diseases of the ear, throat, nose, the drug is administered in a dose of 2-10 ml 1-3 times a day. Bacteriophage is used to rinse, rinse, instill, inject wetted turund (leaving them for 1 hour).
6. With enteral infections, intestinal dysbiosis, the drug is taken orally 3 times a day for 1 hour before meals. A combination of a double oral administration with a single rectal administration of a single age-related dose of a bacteriophage in the form of an enema after bowel evacuation is possible.
Use of bacteriophage in children (up to 6 months).
In sepsis, enterocolitis of newborns, including premature infants, the bacteriophage is used in the form of high enemas (through the gas outlet tube or catheter) 2-3 times a day in a dose of 5-10 ml. In the absence of vomiting and regurgitation, the use of the drug through the mouth is possible. In this case, it is mixed with breast milk. Perhaps a combination of rectal (in the form of high enemas) and oral (through the mouth) application of the drug. The course of treatment is 5-15 days. With a recurring course of the disease, repeated courses of treatment are possible. In order to prevent sepsis and enterocolitis with intrauterine infection or the danger of nosocomial infection in newborns, the bacteriophage is used as an enema 2 times a day for 5-7 days.
In the treatment of omphalitis, pyoderma, infected wounds, the drug is applied twice daily (the gauze cloth is moistened with a bacteriophage and applied to the umbilical wound or the affected area of ​​the skin).
SIDE EFFECT
Not installed.
CONTRAINDICATIONS
hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The use of this medication during pregnancy and during breast-feeding is possible in the presence of infections caused by phagosensitive strains of bacteria (on the recommendation of a doctor).
APPLICATION FOR CHILDREN
Possible use in children according to indications.
SPECIAL INSTRUCTIONS
Precautions for use
In case of turbidity, do not use the drug!
Due to the content of the nutrient medium in which the bacteria can develop from the environment, causing the drug to cloud, it is necessary to observe the following rules when opening the vial:
- Wash hands thoroughly;
- treat the cap with an alcohol-containing solution;
- remove the cap without opening the plug;
- do not place the inner surface of the cork on a table or other objects;
- do not leave the vial open;
- Store the vial only in the refrigerator.
When using small doses (2-8 drops) the drug should be taken with a sterile syringe in a volume of 0.5-1 ml.
The preparation from the opened bottle under observance of storage conditions, the above rules and absence of turbidity can be used during the whole shelf life.
Impact on the ability to drive vehicles and manage mechanisms
Absent.
OVERDOSE
Not installed.
DRUG INTERACTION
The use of the drug is possible in combination with other drugs, including antibiotics.
TERMS OF RELEASE FROM PHARMACY
Without recipe.
TERMS AND CONDITIONS OF STORAGE
The preparation is stored in accordance with SP 3.3.2.1248-03 in a dry place protected from light and inaccessible to children at a temperature of 2 to 8 В° C. Shelf life - 2 years.
